GHRL and obesity due to melanocortin 4 receptor deficiency: Altogether, to date, the evidence that blockade or antagonism of ghrelin signaling at either the peptide or receptor level could be an effective treatment against obesity must be considered weak, with effect sizes that even in the best cases are modest compared to treatments that target other gut hormones [290,291,292].